cinobufotalin profile

cinobufotalin: RN given refers to (3beta,5beta,15beta,16beta)-isomer; RN for cpd without isomeric designation not avail 4/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	259776
CHEMBL ID	517341
SCHEMBL ID	643121
MeSH ID	M0175145

Synonym
bufa-20, 16-(acetyloxy)-14,15-epoxy-3,5-dihydroxy-, (3.beta.,5.beta.,15.beta.,16.beta.)-
cinobufotalin
nsc-90326
nsc90326
cinobufotlin
5.beta.-bufa-20, 14,15.beta.-epoxy-3.beta.,5,16.beta.-trihydroxy-, 16-acetate
l0qbz37386 ,
unii-l0qbz37386
nsc 90326
5-beta-bufa-20,22-dienolide, 14,15-beta-epoxy-3-beta,5,16-beta-trihydroxy-, 16-acetate
bufa-20,22-dienolide, 16-(acetyloxy)-14,15-epoxy-3,5-dihydroxy-, (3beta,5beta,15beta,16beta)-
cinobufagin metabolite m-2
CHEMBL517341
cinobufotalin [who-dd]
(3.beta.,5.beta.,15.beta.,16.beta.)-16-(acetyloxy)-14,15-epoxy-3,5-dihydroxybufa-20,22-dienolide
14,15.beta.-epoxy-3.beta.,5,16.beta.-trihydroxy-5.beta.-bufa-20,22-dienolide 16-acetate
cinobufotalin [mi]
SCHEMBL643121
CS-3698
HY-N0880
AKOS030526073
mfcd28396383
Q63409230
AMY40640
(1r,2r,2ar,3as,3br,5as,7s,9ar,9bs,11ar)-5a,7-dihydroxy-9a,11a-dimethyl-1-(2-oxo-2h-pyran-5-yl)hexadecahydronaphtho[1',2':6,7]indeno[1,7a-b]oxiren-2-yl acetate
[(1r,2s,4r,5r,6r,7r,10s,11r,14s,16s)-14,16-dihydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.02,4.02,7.011,16]octadecan-5-yl] acetate
AS-77576
DTXSID101026581

Excerpt	Reference	Relevance
" Compared with chemotherapy alone, its combination with CFI significantly prolonged the patients' 1-, 2- and 3-year overall survival rate (OS) (1-year OS, OR = 1."	( Cinobufotalin injection combined with chemotherapy for the treatment of advanced NSCLC in China: A PRISMA-compliant meta-analysis of 29 randomized controlled trials. Xu, T; Yin, Y; Zhang, F, 2019)	0.51

Bioassays (22)

Assay ID	Title	Year	Journal	Article
AID1221881	Drug level in human recombinant CYP2B6 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID155910	Inhibitory activity against the primary liver carcinoma (PLC) cell line PLC/PRF/5	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
AID1221926	Drug level in Colony-bred Chinese Bama minipig liver microsomes treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221882	Drug level in human recombinant CYP2C8 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID343717	Cytotoxicity against human Bel7402 cells by MTT assay	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Microbial transformation of cinobufagin by Syncephalastrum racemosum.
AID1221880	Drug level in human recombinant CYP2A6 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221884	Drug level in human recombinant CYP2C19 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221885	Drug level in human recombinant CYP2D6 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID357630	Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay	2001	Journal of natural products, Sep, Volume: 64, Issue:9	Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su.
AID1221886	Drug level in human recombinant CYP2E1 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221928	Drug level in cynomolgus monkey liver microsomes treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221865	Cytotoxicity against human Bel7402 cells assessed as againsthibition of cell growth after 72 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221924	Drug level in Swiss-Hauschka (ICR) mouse liver microsomes treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221927	Drug level in beagle dog liver microsomes treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID357629	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	2001	Journal of natural products, Sep, Volume: 64, Issue:9	Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su.
AID1221929	Drug level in human liver microsomes treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-ESI-MS analysis in presence of NADPH-generating system	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221925	Retention time in Sprague-Dawley rat liver microsomes treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221883	Drug level in human recombinant CYP2C9 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID357628	Cytotoxicity against human KB cells after 72 hrs by MTT assay	2001	Journal of natural products, Sep, Volume: 64, Issue:9	Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su.
AID1221879	Drug level in human recombinant CYP1A2 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID1221878	Drug level in human recombinant CYP3A4 expressed in insect cells coexpressing NADPH-P450 reductase measured per pmol of enzyme treated with 100 uM cinobufagin at 37 degC after 30 mins by UFLC-DAD-ESI-MS analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4	Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human.
AID155909	Inhibitory activity against colchicine resistant parent primary liver carcinoma (PLC) cell line PLC/PRF/5	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (3.03)	18.7374
1990's	5 (15.15)	18.2507
2000's	5 (15.15)	29.6817
2010's	12 (36.36)	24.3611
2020's	10 (30.30)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (3.03%)	5.53%
Reviews	1 (3.03%)	6.00%
Case Studies	1 (3.03%)	4.05%
Observational	0 (0.00%)	0.25%
Other	30 (90.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
bufotenin Bufotenin: A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a tool in CNS studies and misused as a psychedelic.. bufotenin : A tertiary amine that consists of N,N-dimethyltryptamine bearing an additional hydroxy substituent at position 5.	1.99	1	tertiary amine; tryptamine alkaloid	coral metabolite; hallucinogen
periplogenin periplogenin: structure	2.01	1
1-phenyl-2-decanoylamino-3-morpholino-1-propanol RV 538: noninactivating inhibitor of ceramide-UDPG glucosyltransferase; RN given for unspecified HCl; structure given in first source	2.11	1
hellebrigenin hellebrigenin: structure	2.01	1
Gamabufogenin gamabufotalin: antiangiogenic, main active compound isolated from Chinese medicine Chansu; structure in first source	2.41	2	steroid lactone
telocinobufagin telocinobufagin: structure	8.09	5	steroid lactone
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	6.97	1	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	6.99	1	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
sesquiterpenes [no description available]	2.04	1
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.4	2	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
digitoxigenin Digitoxigenin: 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. A cardenolide which is the aglycon of digitoxin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin.. digitoxigenin : A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22).	2.01	1	14beta-hydroxy steroid; 3beta-hydroxy steroid
sanglifehrin a sanglifehrin A: binds cyclophilin A; isolated from Streptomyces; structure in first source	2.1	1
bufogenin bufogenin: respiratory stimulant; from toad; structure. bufogenin : A steroid lactone of Chan su (toad venom), a Chinese medicine obtained from the skin venom gland of toads. A specific Na/K-ATPase protein inhibitor, it is used as a cardiotonic and central nervous system (CNS) respiratory agent, an analgesic and anesthetic, and as a remedy for ulcers.	8.16	5	epoxy steroid; steroid lactone	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
beta-elemene beta-elemene: increases tumor cell immunogenicity by inducing, at least in part, elevated expression of heat shock protein 70 on tumor cell surface. beta-elemene : A sesquiterpene that consists of cyclohexane bearing methyl and vinyl substituents at position 1 as well as two isopropenyl substituents at positions 2 and 4.. (-)-beta-elemene : The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration.	2.04	1	beta-elemene	antineoplastic agent
bufalin bufalin: cardiotonic; powerful anesthetic & one of the active constituents of the Chinese drug ch'an su(senso); in Japan prepared from skin of Bufo bufo garfarizans; RN given refers to (3beta,5beta)-isomer. bufalin : A 14beta-hydroxy steroid that is bufan-20,22-dienolide having hydroxy substituents at the 5beta- and 14beta-positions. It has been isolated from the skin of the toad Bufo bufo.	3.49	8	14beta-hydroxy steroid; 3beta-hydroxy steroid	animal metabolite; anti-inflammatory agent; antineoplastic agent; cardiotonic drug
oleandrigenin oleandrigenin: RN given refers to (3beta)-isomer; structure. oleandrigenin : A steroid ester that is the 16-acetyl derivative of gitoxigenin.	6.99	1	14beta-hydroxy steroid; 3beta-hydroxy steroid; steroid ester	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; metabolite
oleandrin oleandrin: structure. oleandrin : A steroid saponin that consists of oleandrigenin having a 2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl residue attached to the oxygen function at position 3.	6.99	1	14beta-hydroxy steroid; cardenolide glycoside; steroid ester; steroid saponin
desacetylcinobufagin desacetylcinobufagin: structure in first source	2.71	3
cinobufagin cinobufagin: isolated from Chinese medicinal preparation ch'an su; derived from toad venom	8.62	9	steroid lactone
bufotalin bufotalin: from toads; structure	2.73	3	steroid lactone
bufadienolide bufadienolide: isolated from liushen pills; RN given for (14beta)-isomer. bufadienolide : The simplest member of the class of bufadienolides that is bufanolide with unsaturation at positions 20 and 22.	2.04	1	bufadienolides
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.1	1

Condition	Relationship Strength	Studies	Trials
Granulocytic Leukemia [description not available]	2	1	0
Cancer of Nasopharynx [description not available]	2.47	2	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2	1	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2.47	2	0
Cancer of Liver [description not available]	3.48	7	0
Liver Neoplasms Tumors or cancer of the LIVER.	3.48	7	0
Glial Cell Tumors [description not available]	2.31	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	7.31	1	0
Bone Cancer [description not available]	2.41	1	0
Osteogenic Sarcoma [description not available]	2.41	1	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.41	1	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	7.41	1	0
Hepatocellular Carcinoma [description not available]	3.38	6	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	3.38	6	0
Lung Adenocarcinoma [description not available]	7.41	1	0
Cancer of Lung [description not available]	4.06	4	0
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	2.41	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	4.06	4	0
Carcinoma, Non-Small Cell Lung [description not available]	3.12	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.12	1	0
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	2.21	1	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.31	1	0
Cancer of Ovary [description not available]	2.17	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.17	1	0
Breast Cancer [description not available]	7.21	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.21	1	0
Adenocarcinoma, Basal Cell [description not available]	2.47	2	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.47	2	0
Cancer of Endometrium [description not available]	2.05	1	0
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	2.05	1	0
Cancer of Stomach [description not available]	2.04	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.04	1	0
Hepatitis B Virus Infection [description not available]	3.37	1	1
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	8.37	1	1
Bradyarrhythmia [description not available]	1.99	1	0
Emesis [description not available]	1.99	1	0
Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.	1.99	1	0
Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	1.99	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	1.99	1	0

cinobufotalin

Description

Cross-References

Synonyms (28)

Research Excerpts

Compound-Compound Interactions

Bioassays (22)

Research

Studies (33)

Study Types

cinobufotalin

Description

Cross-References

Synonyms (28)

Research Excerpts

Compound-Compound Interactions

Bioassays (22)

Research

Studies (33)

Study Types

Related Drugs (22)

Related Conditions (39)